Bicycle Therapeutics PLC (BCYC)
23.46
+0.75
(+3.30%)
USD |
NASDAQ |
Nov 04, 16:00
23.50
+0.04
(+0.15%)
After-Hours: 20:00
Bicycle Therapeutics Enterprise Value: 728.96M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 728.96M |
| November 01, 2024 | 677.17M |
| October 31, 2024 | 727.92M |
| October 30, 2024 | 768.31M |
| October 29, 2024 | 798.69M |
| October 28, 2024 | 820.79M |
| October 25, 2024 | 815.90M |
| October 24, 2024 | 818.66M |
| October 23, 2024 | 856.62M |
| October 22, 2024 | 918.05M |
| October 21, 2024 | 951.87M |
| October 18, 2024 | 974.64M |
| October 17, 2024 | 954.63M |
| October 16, 2024 | 1.008B |
| October 15, 2024 | 978.78M |
| October 14, 2024 | 916.67M |
| October 11, 2024 | 935.30M |
| October 10, 2024 | 837.30M |
| October 09, 2024 | 805.55M |
| October 08, 2024 | 733.08M |
| October 07, 2024 | 724.11M |
| October 04, 2024 | 737.92M |
| October 03, 2024 | 641.29M |
| October 02, 2024 | 666.14M |
| October 01, 2024 | 676.49M |
| Date | Value |
|---|---|
| September 30, 2024 | 670.97M |
| September 27, 2024 | 670.88M |
| September 26, 2024 | 678.47M |
| September 25, 2024 | 680.54M |
| September 24, 2024 | 697.79M |
| September 23, 2024 | 723.32M |
| September 20, 2024 | 822.67M |
| September 19, 2024 | 828.88M |
| September 18, 2024 | 750.23M |
| September 17, 2024 | 753.68M |
| September 16, 2024 | 792.31M |
| September 13, 2024 | 933.75M |
| September 12, 2024 | 948.93M |
| September 11, 2024 | 929.61M |
| September 10, 2024 | 934.44M |
| September 09, 2024 | 888.21M |
| September 06, 2024 | 486.67M |
| September 05, 2024 | 479.08M |
| September 04, 2024 | 490.12M |
| September 03, 2024 | 506.68M |
| August 30, 2024 | 552.91M |
| August 29, 2024 | 563.94M |
| August 28, 2024 | 598.44M |
| August 27, 2024 | 621.90M |
| August 26, 2024 | 626.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.585M
Minimum
Jun 16 2022
1.568B
Maximum
Nov 15 2021
487.04M
Average
450.14M
Median
Jul 03 2023
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 18.55M |
| NuCana PLC | -11.24M |
| TC BioPharm (Holdings) PLC | -0.5511M |
| Autolus Therapeutics PLC | 182.82M |
| Mereo BioPharma Group PLC | 534.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -50.80M |
| Revenue (Quarterly) | 2.676M |
| Total Expenses (Quarterly) | 66.20M |
| EPS Diluted (Quarterly) | -0.74 |
| Profit Margin (Quarterly) | -1.90K% |
| Earnings Yield | -14.02% |
| Normalized Earnings Yield | -13.98 |